T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$2.31B |
| 2 |
Apple
AAPL
|
+$1.58B |
| 3 |
Sherwin-Williams
SHW
|
+$1.37B |
| 4 |
HubSpot
HUBS
|
+$1.32B |
| 5 |
Kenvue
KVUE
|
+$1.25B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.37B |
| 2 |
Lam Research
LRCX
|
+$1.54B |
| 3 |
Applied Materials
AMAT
|
+$1.33B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$1.19B |
| 5 |
Halliburton
HAL
|
+$1.16B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.32% |
| 2 | Healthcare | 15.15% |
| 3 | Financials | 10.54% |
| 4 | Consumer Discretionary | 10.48% |
| 5 | Communication Services | 8.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
VICI Properties
VICI
$29B
| $181M | 0.02% |
5,439,551
+3,890,992
| +251% | +$123M |
|
452
Ralph Lauren
RL
$23.1B
| $180M | 0.02% |
929,169
-27,055
| -3% | -$4.68M |
|
453
Owens Corning
OC
$12.3B
| $178M | 0.02% |
1,008,058
+927,799
| +1,156% | +$156M |
|
454
Assurant
AIZ
$13.9B
| $178M | 0.02% |
893,137
-11,222
| -1% | -$2.04M |
|
455
Altria Group
MO
$109B
| $175M | 0.02% |
3,431,506
+314,985
| +10% | +$15.9M |
|
456
Vera Therapeutics
VERA
$2.08B
| $174M | 0.02% |
3,939,109
+318,974
| +9% | +$12.1M |
|
457
Cameco
CCJ
$42.6B
| $174M | 0.02% |
3,642,052
-1,433,712
| -28% | -$62.5M |
|
458
Zscaler
ZS
$30.4B
| $174M | 0.02% |
1,017,156
+359,730
| +55% | +$65.7M |
|
459
PNC Financial Services
PNC
$102B
| $173M | 0.02% |
933,785
-936,671
| -50% | -$164M |
|
460
TC Energy
TRP
$65.8B
| $172M | 0.02% |
3,614,870
+37,633
| +1% | +$1.64M |
|
461
Biohaven
BHVN
$2.24B
| $172M | 0.02% |
3,438,526
+154,047
| +5% | +$5.99M |
|
462
Main Street Capital
MAIN
$5.54B
| $171M | 0.02% |
3,412,553
-973
| -0% | -$48.6K |
|
463
Cardinal Health
CAH
$53.8B
| $171M | 0.02% |
1,545,541
-574,861
| -27% | -$60.1M |
|
464
Ultragenyx Pharmaceutical
RARE
$2.6B
| $170M | 0.02% |
3,068,654
+76,696
| +3% | +$3.91M |
|
465
Ionis Pharmaceuticals
IONS
$9.28B
| $169M | 0.02% |
4,210,172
+275,861
| +7% | +$12.8M |
|
|
MRO
466
DELISTED
Marathon Oil Corporation
MRO
| $168M | 0.02% |
6,314,059
+2,432,737
| +63% | +$67.3M |
|
467
ZTO Express
ZTO
$17.4B
| $167M | 0.02% |
6,757,871
-465,716
| -6% | -$9.65M |
|
468
Kohl's
KSS
$2.22B
| $167M | 0.02% |
7,930,905
-1,021,643
| -11% | -$20.8M |
|
469
Cytokinetics
CYTK
$10.2B
| $167M | 0.02% |
3,164,945
+806,602
| +34% | +$45M |
|
470
Huntington Ingalls Industries
HII
$12.8B
| $166M | 0.02% |
627,595
-273,443
| -30% | -$72.4M |
|
471
AerCap
AER
$23.5B
| $165M | 0.02% |
1,742,453
+10,978
| +0.6% | +$1.03M |
|
472
Quanta Services
PWR
$101B
| $164M | 0.02% |
549,677
+22,909
| +4% | +$6.06M |
|
473
Ameriprise Financial
AMP
$50.4B
| $163M | 0.02% |
347,526
+44,922
| +15% | +$19.5M |
|
474
Lamb Weston
LW
$7.39B
| $163M | 0.02% |
2,513,849
+2,313,317
| +1,154% | +$153M |
|
475
Pultegroup
PHM
$24.9B
| $162M | 0.02% |
1,125,914
+798,000
| +243% | +$101M |
|
Similar funds
T. Rowe Price Associates's Q3 2024 Portfolio in Review
As of Q3 2024, T. Rowe Price Associates held 3,059 positions worth $869B, up 3.9% from $836B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Trading was light in Q3 2024: portfolio turnover was 4.3%. T. Rowe Price Associates opened 82 new positions and exited 51, leaving the 3,059-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 34% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q3 2024 buy was Lineage Inc: 4,699,854 shares worth $368M.
- T. Rowe Price Associates added most to Advanced Micro Devices in Q3 2024, an estimated $2.31B increase.
- T. Rowe Price Associates's biggest Q3 2024 reduction was NVIDIA, cutting an estimated $4.37B.
- T. Rowe Price Associates fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $75.2M.
- T. Rowe Price Associates's ten largest holdings make up 34% of its $869B portfolio in Q3 2024.
- T. Rowe Price Associates opened 82 new positions and closed 51 in Q3 2024.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $869B.
Based on T. Rowe Price Associates's 13F filing for Q3 2024, filed 14 Nov 2024.